A pioneering immuno-oncology researcher heads back to Dana-Farber as Eli Lilly’s cancer R&D group undergoes a wrenching changeup
Leena Gandhi played a major role in exploring the therapeutic potential of Keytruda, Merck’s megastar cancer drug. Six years ago at Dana-Farber she mapped out the connection between PD-L1 expression and efficacy in KEYNOTE-001 while later exploring the tumor microenvironment and the impact of chemo combinations on cancer. And she continued her work in immuno-oncology, leading the way on important research projects and heralding a new era in Eli Lilly’s cancer group when she migrated to the pharma giant 2 years ago.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.